Hematologic Oncology | Specialty

Novartis Sets a Price of $475,000 for CAR T-Cell Therapy

August 31st 2017

Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.

Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

August 30th 2017

Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.

FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy

August 30th 2017

The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

FDA Grants Frontline Bosutinib Priority Review in CML

August 30th 2017

The FDA has granted a priority review to a supplemental new drug application for bosutinib for the first-line treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The Value of MRD Testing in Lymphoid Malignancies

August 29th 2017

MRD Negativity in Multiple Myeloma

August 29th 2017

Reliability of MRD Testing: Sensitivity/Specificity

August 29th 2017

Varying Pertinence: MRD Testing Across Lymphomas

August 29th 2017

How to Properly Utilize MRD Testing

August 29th 2017

An Overview of Minimal Residual Disease Testing

August 29th 2017

Understanding MRD Testing in CLL

August 29th 2017

CLL: MRD Testing Platforms

August 29th 2017

MRD Timepoints in CLL

August 29th 2017

CLL: Value of MRD Testing

August 29th 2017

Goals of Therapy in CLL

August 29th 2017

Gilead Acquires Kite Pharma in $11.9 Billion Deal

August 28th 2017

Gilead has announced plans to acquire Kite Pharma for $180.00 per share in cash, totaling approximately $11.9 billion.

Dr. Erba Discusses Efficacy of CPX-351 in Additional Subsets of AML

August 25th 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses additional subsets of acute myeloid leukemia (AML) that CPX-351 (Vyxeos) demonstrates efficacy in.

Dr. Roboz on Evolving Paradigms in AML Treatment

August 25th 2017

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses evolving paradigms in treatment of patients with acute myeloid leukemia (AML).

Published Data Demonstrate Efficacy of Carfilzomib in Myeloma

August 24th 2017

Results from the phase III ENDEAVOR trial showed that carfilzomib (Kyprolis) reduced the risk of death by 21% compared with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma

Dr. Andorsky on Next Steps Following MAGNIFY Trial in Follicular Lymphoma

August 24th 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.